Biomedical Engineering Reference
In-Depth Information
81. Valzasina B, Guiducci C, Dislich H, Killeen N, Weinberg AD,
Colombo MP. (2005) Triggering of OX40 (CD134) on
CD4 þ CD25 þ T cells blocks their inhibitory activity: a novel
regulatory role for OX40 and its comparison with GITR.
Blood 105, 2845-2851.
82. Sadun RE, Hsu WE, Zhang N, Nien YC, Bergfeld SA,
Sabzevari H, et al. (2008) Fc-mOX40L fusion protein pro-
duces complete remission and enhanced survival in 2 murine
tumor models. J. Immunother. 31, 235-245.
83. McCarron PA, Olwill SA, Marouf WM, Buick RJ, Walker B,
Scott CJ. (2005) Molecular conjugates and therapeutic strat-
egies. Mol. Intervent. 5, 368-380.
84. Biela BH, Khawli LA, Hu P, Epstein AL. (2003) Chimeric
TNT-3/human b -glucuronidase fusion proteins for antibody-
directed enzyme prodrug therapy (ADEPT). Cancer Biother.
Radiopharm. 18, 339-353.
85. Stone MJ, Ruf W, Miles DJ, Edgington TS, Wright PE.
(1995) Recombinant soluble human tissue factor secreted
by Saccharomyces cerevisiae and refolded from
Escherichia coli inclusion bodies: glycosylation of mutants,
activity and physical characterization. Biochem. J. 310,
605-614.
86. Wigginton JM, Komschlies KL, Back TC, Franco JL, Brunda
MJ, Wiltrout RH. (1996) Administration of interleukin 12
with pulse interleukin 2 and the rapid and complete erad-
ication of murine renal carcinoma. J. Natl. Cancer Inst. 88,
38-43.
87. Ohe Y, Podack ER, Olsen KJ, Miyahara Y, Ohira T, Miura K,
et al. (1993) Combination effect of vaccination with IL2 and
IL4 cDNA transfected cells on the induction of a therapeutic
immune response against Lewis lung carcinoma cells. Int. J.
Cancer 53, 432-437.
88. Wakimoto H, Abe J, Tsunoda R, Aoyagi M, Hirakawa K,
Hamada H. (1996) Intensified antitumor immunity by a
cancer vaccine that produces granulocytemacrophage col-
ony-stimulating factor plus interleukin 4. Cancer Res. 56,
1828-1833.
89. Hill HC, Conway TF, Sabel MS, Jong YS, Mathiowitz E,
Bankert RB, et al. (2002) Cancer immunotherapy with inter-
leukin 12 and granulocyte-macrophage colony-stimulating
factor-encapsulated microspheres: coinduction of innate and
adaptive antitumor immunity and cure of disseminated dis-
ease. Cancer Res. 62, 7254-7263.
90. Gillies SD, Lan Y, Brunkhorst B, Wong WK, Li Y, Lo KM.
(2002) Bi-functional cytokine fusion proteins for gene ther-
apy and antibody-targeted treatment of cancer. Cancer Immu-
nol. Immunother. 51, 449-460.
91. Khawli LA, Hu P, Epstein AL. (2008) Therapeutic Anti-
bodies. Handbook of Experimental Pharmacology. Springer-
Verlag, Berlin Heidelberg, 291-328.
92. Hill JO, Awwad M, North RJ. (1989) Elimination of CD4 þ
suppressor T cells from susceptible BALB/c mice releases
CD8 þ T lymphocytes to mediate protective immunity against
Leishmania. J. Exp. Med. 169, 1819-1827.
93. Rakhmilevich AL, North RJ. (1993) Presence of CD4 þ
T suppressor cells in mice rendered unresponsive to tumor
antigens by intravenous injection of irradiated tumor cells.
Int. J. Cancer 55, 338-343.
94. Rakhmilevich AL, North RJ. (1994) Elimination of CD4 þ
T cells in mice bearing an advanced sarcoma augments the
antitumor action of interleukin-2. Cancer Immunol. Immun-
other. 38, 107-112.
95. Shevach EM. (2002) CD4 þ CD25 þ suppressor T cells: more
questions than answers. Nat. Rev. Immunol. 2, 389-400.
96. Javia LR, Rosenberg SA. (2003) CD4 þ CD25 þ Suppressor
lymphocytes in the circulation of patients immunized against
melanoma antigens. J. Immunother. 26, 85-93.
97. Hara M, Kingsley C. (2001) IL-10 is required for regulatory
T cell to mediate tolerance to alloantigens in vivo. J. Immun-
other. 166, 3789-3796.
98. Somasundaram R, Jacob L. (2002) Inhibition of cytolytic T
lymphocyte proliferation by autologous CD4 þ CD25 þ regu-
latory T cells in a colorectal carcinoma patient is mediated by
transforming growth factor- b . Cancer Res. 62, 5267-5272.
99. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T,
Nakayama E. (1999) Tumor rejection by in vivo administra-
tion of anti-CD25 (interleukin-2 receptor alpha) monoclonal
antibody. Cancer Res. 59, 3128-3133.
100. Shimizu J, Yamazaki S, Sakaguchi S. (1999) Induction of
tumor immunity by removing CD25 þ CD4 þ T cells: a com-
mon basis between tumor immunity and autoimmunity.
J. Immunol. 163, 5211-5218.
101. Awwad M, North RJ. (1990) Radiosensitive barrier to T-cell-
mediated adoptive immunotherapy of established tumors.
Cancer Res. 50, 2228-2233.
102. Levings MK, Sangregorio R, Roncarolo MG. (2001) Human
CD25 þ CD4 þ T cells suppress na ıve and memory T-cell
proliferation and can be expanded in vitro without loss of
suppressor function. J. Exp. Med. 193, 1295-1302.
103. Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G.
(2001) Ex vivo isolation and characterization of CD4 þ CD25 þ
T cells with regulatory properties from human blood. J. Exp.
Med. 193, 1303-1310.
104. Jonuleit H. (2001) Identification and functional characteriza-
tion of human CD4 þ CD25 þ T cells with regulatory properties
isolated from peripheral blood. J. Exp. Med. 193, 1285-1294.
105. Stephens LA, Mottet C, Mason D, Powrie F. (2001) Human of
CD4 þ CD25 þ thymocytes and peripheral T cells have
immune suppressive activity. Eur. J. Immunol. 31, 1247-
1254.
106. Ng WF. (2001) Human of CD4 þ CD25 þ cells: a naturally
occurring population of regulatory T cells. Blood 98, 2736-
2744.
107. Baecher-Allen C, Brown JA, Freeman GJ, Haefler DA. (2001)
CD4 þ CD25 þ regulatory cells in human peripheral blood.
J. Immunol. 167, 1245-1253.
108. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V,
Doherty G, et al. (2002) Prevalence of regulatory T cells is
increased in peripheral blood and tumor microenvironment of
patients with pancreas or breast adenocarcinoma. J. Immunol.
169, 2756-2761.
Search WWH ::




Custom Search